Provention Bio, Inc.
PRVB
|
$24.98
0.08%
9.1M
|
Health Technology
(0.0% 1d) (0.0% 1m) (2.2% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (NaN% volume)
Earnings Calendar: 2023-05-04
Market Cap: $ 2,367,626,233
http://www.proventionbio.com
Sec Filling | Patents | 19 employees
(US) Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D); PRV-015 for the treatment of gluten-free diet non-responding celiac disease; PRV-6527 for Crohn’s disease; PRV-3279 for the treatment of lupus; and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Lebanon, NJ.
diabetes diabetic treatment
add to watch list Paper trade email alert is off
Sigilon Therapeutics Inc
SGTX
|
$22.47
-2.56%
0.0%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (236.8% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (32.61% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 56,500,770
https://sigilon.com
Sec Filling | Patents | 2021 employees
Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, lysosomal disorders and diabetes. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.
diabetic diabetes ceiling t-cell
add to watch list Paper trade email alert is off
XORTX Therapeutics Inc.
XRTX | $3.5 -3.05% -3.14% 12K
|
Mining, Quarrying, and Oil and ...
(0.0% 1d) (-21.8% 1m) (418.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (Infinity% volume)
Earnings Calendar:
Market Cap: $ 6,995,968
http://www.xortx.com
Sec Filling | Patents | n/a employees
(CA) XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for acute kidney injury associated with Coronavirus / COVID-19 infection and XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. XORTX Therapeutics is dedicated to developing medications to improve the quality of life and future health of patients.
injection kidney diabetes diabetic metabolic covid
add to watch list Paper trade email alert is off
Sino Biopharmaceutical Limited/ADR
SBMFF
|
$0.3624
64.18%
45K
|
Health Technology
(0.0% 1d) (0.0% 1m) (-33.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (19324.79% volume)
Earnings Calendar:
Market Cap: $ 6,813,561,124
http://www.sinobiopharm.com
Sec Filling | Patents | n/a employees
(HK) Sino Biopharmaceutical Ltd. is an investment holding company, which engages in the manufacture and sale of pharmaceutical products. It operates through the following business segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The Modernised Chinese Medicines and Chemical Medicines segment comprises the manufacturing, selling, and distribution of modernized Chinese medicine products and western medicine products. The Investment segment offers long term investments. The Other segment includes a research and development sector, which provides services to third-parties; and related healthcare and hospital business. It also develops medicines for treating tumors, analgesia, diabetes, and respiratory system diseases. The company was founded by Ping Tse on February 2, 2000 and is headquartered in Hong Kong.
respiratory diabetic diabetes
add to watch list Paper trade email alert is off
ConvaTec Group PLC/ADR
CNVVF
|
$3.685
-18.0%
6.4K
|
Health Technology
(0.0% 1d) (-3.0% 1m) (31.6% 1y) (0.0% 2d) (0.0% 3d) (-5.0% 7d) (2130.18% volume)
Earnings Calendar:
Market Cap: $ 7,553,474,525
http://www.convatec.com
Sec Filling | Patents | n/a employees
(GB) ConvaTec Group Plc operates as holding company, which engages in medical business. Its activities include development, manufacture and sales of medical products and technologies related to therapies for the management of chronic conditions, including products used for advanced chronic and acute wound care, ostomy care and management, continence and critical care, and infusion devices used in the treatment of diabetes and other conditions. The company was incorporated in 1978 and is headquartered in Reading, the United Kingdom.
treatment diabetic diabetes
add to watch list Paper trade email alert is off
Intelligent Bio Solutions Inc
INBS
|
$2.8
4.48%
110K
|
Manufacturing
(0.0% 1d) (-36.2% 1m) (-11.8% 1y) (0.0% 2d) (-8.8% 3d) (-11.8% 7d) (-100.0% volume)
Earnings Calendar: 2024-02-13
Market Cap: $ 7,963,911
https://gbs.inc
Sec Filling | Patents | 8 employees
(US) GBS Inc. is on a mission to put the power of non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point of care. With the world-first Biosensor Platform, GBS Inc. is developing and launching diagnostic tests urgently needed to help eradicate COVID-19 and change the lives of people living with diabetes.
diagnostics diabetes diabetic covid
add to watch list Paper trade email alert is off
PetMed Express, Inc.
PETS
|
$4.19
-0.71%
58K
|
Retail Trade
(0.0% 1d) (-11.2% 1m) (-72.6% 1y) (0.0% 2d) (1.2% 3d) (2.4% 7d) (19.46% volume)
Earnings Calendar: 2024-03-29
Market Cap: $ 88,613,019
http://www.1800petmeds.com
Sec Filling | Patents | 214 employees
PetMed Express, Inc. engages in the provision of markets prescription and non-prescription pet medications, health products and supplies for dogs and cats. Its non-prescription medications include flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies. The prescription medications include heartworm preventatives, arthritis, thyroid, diabetes and pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The firm markets its products through national television, online and direct mail or print advertising campaigns. The company was founded in January 1996 and is headquartered in Delray Beach, FL.
nutrition heart diabetes diabetic pets bone
add to watch list Paper trade email alert is off
Insulet Corporation
PODD
|
$169.175
1.75%
150K
|
Health Technology
(0.0% 1d) (-2.5% 1m) (-49.0% 1y) (0.0% 2d) (-3.7% 3d) (-5.1% 7d) (5.0% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 11,846,055,253
http://www.insulet.com
Sec Filling | Patents | 1350 employees
(US) Insulet Corp. is a medical device company. The firm engages in the development, manufacture and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.
insulin diabetes diabetic
add to watch list Paper trade email alert is off
Opthea Limited
OPT
|
$3.39
-0.29%
1.8K
|
Health Technology
(0.0% 1d) (0.3% 1m) (-4.2% 1y) (0.0% 2d) (-3.1% 3d) (-11.2% 7d) (637.02% volume)
Earnings Calendar:
Market Cap: $ 280,865,158
http://www.opthea.com
Sec Filling | Patents | 18 employees
(AU) Opthea Ltd. is a clinical stage biopharmaceutical company that engages in the development of biological therapeutics for the treatment of progressive retinal diseases. It targets to treat neovascular age-related macular degeneration (wet AMD) and diabetic macular edema, which causes visual impairment among elderly and diabetic patients. The company was founded on October 17, 1984 and is headquartered in South Yarra, Australia.
diabetes diabetic macular dmd treatment
add to watch list Paper trade email alert is off
PharmaCyte Biotech Inc
PMCB
|
$2.12
2.9K
|
Manufacturing
(0.0% 1d) (-0.9% 1m) (-28.4% 1y) (0.0% 2d) (-1.4% 3d) (-4.9% 7d) (-28.3% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 17,921,200
https://www.pharmacytebiotech.com
Sec Filling | Patents | 4 employees
PharmaCyte Biotech, Inc. is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as "Cell-in-a-Box®." This technology is being used as a platform upon which therapies for several types of cancer and diabetes are being developed. PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or "cancer-killing" form.
diabetic diabetes msa ceiling cancer genetic t-cell
add to watch list Paper trade email alert is off
SAB Biotherapeutics Inc
SABS | $4.6 2K
|
(0.0% 1d) (-4.2% 1m) (374.3% 1y) (0.0% 2d) (-5.7% 3d) (-1.6% 7d) (-47.36% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 42,437,272
https://www.sabbiotherapeutics.com
Sec Filling | Patents | 5 employees
SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine™ that produce fully-human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer. SAB’s versatile DiversitAb™ platform is applicable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB is currently advancing multiple clinical programs and has collaborations with the US government and global pharmaceutical companies.
genetic cancer diabetes diabetic influenza covid
add to watch list Paper trade email alert is off
Rezolute Inc.
RZLT
4
|
$3.38
4.32%
120K
|
Technology Services
(0.0% 1d) (70.5% 1m) (69.6% 1y) (0.0% 2d) (-4.7% 3d) (20.0% 7d) (-31.06% volume)
Earnings Calendar: 2024-02-09
Market Cap: $ 135,631,447
http://www.rezolutebio.com
Sec Filling | Patents | 23 employees
(US) Rezolute, Inc. is biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its products portfolio include RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperInsulinism; AB101-Phase 1, a once-weekly injectable basal insulin; and RZ402 which targets diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.
insulin antibody diabetes diabetic macular metabolic injection
add to watch list Paper trade email alert is off
Alimera Sciences, Inc.
ALIM
|
$3.4
-4.23%
8.4K
|
Health Technology
(0.0% 1d) (-11.6% 1m) (72.4% 1y) (0.0% 2d) (0.0% 3d) (1.7% 7d) (32.25% volume)
Earnings Calendar: 2023-10-26
Market Cap: $ 178,005,130
http://www.alimerasciences.com
Sec Filling | Patents | 127 employees
(US) Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.
diabetes diabetic macular treatment
Drugs
Iluvien (fluocinolone acetonide)add to watch list Paper trade email alert is off
Biomerica, Inc.
BMRA
|
$0.751
7.7K
|
Health Technology
(0.0% 1d) (-33.5% 1m) (-56.1% 1y) (0.0% 2d) (0.0% 3d) (-10.8% 7d) (-51.91% volume)
Earnings Calendar: 2022-10-13
Market Cap: $ 12,633,056
http://www.biomerica.com
Sec Filling | Patents | 45 employees
Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The firm focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, United States, Asia, South America, Middle East, and Other Foreign. The company was founded in September 1971 and is headquartered in Irvine, CA.
gastrointestinal diabetes diabetic food diagnostics
add to watch list Paper trade email alert is off
Sanofi
SNY
|
News
|
$45.445
-1.44%
2.6M
|
Health Technology
(0.0% 1d) (-2.5% 1m) (-17.2% 1y) (0.0% 2d) (0.5% 3d) (0.3% 7d) (NaN% volume)
Earnings Calendar:
Market Cap: $ 114,957,972,028
http://www.sanofi.com
Sec Filling | Patents | 100409 employees
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
vaccine cardiovascular diabetes diabetic
add to watch list Paper trade email alert is off
Tandem Diabetes Care, Inc.
TNDM
|
$31.31
-1.39%
470K
|
Health Technology
(0.0% 1d) (3.1% 1m) (-23.0% 1y) (0.0% 2d) (-3.7% 3d) (-5.2% 7d) (-35.56% volume)
Earnings Calendar: 2024-02-21
Market Cap: $ 2,021,482,434
http://www.tandemdiabetes.com
Sec Filling | Patents | 1043 employees
(US) Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.
insulin diabetes diabetic msa
add to watch list Paper trade email alert is off
Xeris Pharmaceuticals, Inc.
XERS
|
$1.76
-1.12%
480K
|
Health Technology
(0.0% 1d) (-17.2% 1m) (-20.5% 1y) (0.0% 2d) (-1.1% 3d) (-6.8% 7d) (-17.17% volume)
Earnings Calendar: 2024-03-06
Market Cap: $ 247,198,102
http://www.xerispharma.com
Sec Filling | Patents | 202 employees
Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol and XeriJect formulation technologies. Its products include Gvoke Pre-Filled Syringe and Gvoke HypoPen. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Chicago, IL.
diabetes injection
Drugs
Gvoke HypoPen 0.5 mg Auto-Injector (glucagon injection, solution)Gvoke HypoPen 1 mg Auto-Injector (glucagon injection, solution)
Gvoke PFS 0.5 mg Pre-filled Syringe (glucagon injection, solution)
Gvoke PFS 1 mg Pre-filled Syringe (glucagon injection, solution)
add to watch list Paper trade email alert is off
vTv Therapeutics Inc.
VTVT
|
$24.15
2.1K
|
Health Technology
(0.0% 1d) (15.6% 1m) (3077.6% 1y) (0.0% 2d) (0.1% 3d) (-1.5% 7d) (215.49% volume)
Earnings Calendar: 2024-03-04
Market Cap: $ 58,753,497
http://www.vtvtherapeutics.com
Sec Filling | Patents | 26 employees
(US) vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.
diabetes cancer diabetic alzheimer nervous system molecule drugs metabolic treatment glioblastoma
add to watch list Paper trade email alert is off
DexCom, Inc.
DXCM
|
$134.34
0.36%
1M
|
Health Technology
(0.0% 1d) (1.8% 1m) (10.0% 1y) (0.0% 2d) (0.0% 3d) (0.3% 7d) (18.91% volume)
Earnings Calendar: 2024-02-08
Market Cap: $ 51,790,141,657
http://www.dexcom.com
Sec Filling | Patents | 5200 employees
DexCom, Inc. is a medical device manufacturing company. The firm engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G4 PLATINUM System, DexCom G5 Mobil, DexCom Share and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.
diabetes diabetic
add to watch list Paper trade email alert is off
Evoke Pharma, Inc.
EVOK
|
News
|
$0.549
16K
|
Health Technology
(0.0% 1d) (-22.8% 1m) (-77.6% 1y) (0.0% 2d) (0.0% 3d) (-7.8% 7d) (-2.67% volume)
Earnings Calendar: 2024-03-21
Market Cap: $ 4,654,313
http://www.evokepharma.com
Sec Filling | Patents | 5 employees
Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.
diabetes gastrointestinal diabetic women treatment
Drugs
GIMOTI (METOCLOPRAMIDE HYDROCHLORIDE)add to watch list Paper trade email alert is off
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 72% | 28% |
Top 10 Gainers
AGBA | $1.05 162.5% 100M
|
Finance
ISPC | $0.4621 116.95% 15M
|
Professional, Scientific, and T...
INVO | $1.515 99.34% 4.3M
|
Health Technology
BPTH | $5.62 73.46% 75M
|
Health Technology
TIRX | $0.8231 69.78% 54M
|
SINT | $0.0519 39.14% 350M
|
Health Technology
XPON | $2.63 36.27% 8.4M
|
VTNR S | $1.26 28.68% 9.1M
|
Industrial Services
SWVL | $9.64 27.35% 200K
|
n/a
DFLI A | $0.7726 25.52% 4.3M
|
Last 48 Hours Insiders Buying
QCRH | $55.405 1.33% 13K
|
Finance
|
18:01
RVP P 15363 | $1.04 14K
|
Health Technology
|
18:00
VUZI | $1.33 9.02% 540K
|
Electronic Technology
|
18:00
TPL P 3 | $592.6 1.31% 22K
|
Miscellaneous
|
15:00
RELL | $10.24 3.85% 36K
|
Electronic Technology
|
13:30
IZEA | $2.53 20K
|
Technology Services
|
00:00
RKT P 383 | $11.735 3.12% 640K
|
Finance
|
22:30
CTRN P 18090 | $22.39 0.09% 33K
|
Retail Trade
|
22:00
BRN P 10650 | $2.8 0.36% 44K
|
Energy Minerals
|
21:00
NEOG P 10000 | $11.85 -2.39% 1.7M
|
Health Technology
|
16:30
RMCF | $3.53 1.7K
|
Consumer Non-Durables
|
20:10